Merck and Eisai report mixed results in Phase 3 cancer trial
Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...
Rakuten doses first patients in multi-continental Phase III HNSCC trial
The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...
Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.